These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 2449054)
1. The effects of aprotinin, a glandular kallikrein inhibitor, on renin release and urinary sodium excretion in mild essential hypertensives. Madeddu P; Oppes M; Soro A; Dessi'-Fulgheri P; Glorioso N; Manunta F; Rubatti S; Rappelli A Agents Actions Suppl; 1987; 22():373-80. PubMed ID: 2449054 [TBL] [Abstract][Full Text] [Related]
2. The effects of aprotinin, a kallikrein inhibitor, on renin release and urinary sodium excretion in mild essential hypertensives. Madeddu P; Oppes M; Soro A; Dessi'-Fulgheri P; Glorioso N; Bandiera F; Manunta P; Rubattu S; Rappelli A J Hypertens; 1987 Oct; 5(5):581-6. PubMed ID: 2448367 [TBL] [Abstract][Full Text] [Related]
3. The effect of aprotinin (a serine protease inhibitor) on renal function and renin release. Seto S; Kher V; Scicli AG; Beierwaltes WH; Carretero OA Hypertension; 1983; 5(6):893-9. PubMed ID: 6197374 [TBL] [Abstract][Full Text] [Related]
4. [Selected components of the kallikrein-kinin system and of the renin-angiotensin-aldosterone system in offspring of parents with hypertension]. Marzecka J Ann Acad Med Stetin; 1996; 42():123-38. PubMed ID: 9199117 [TBL] [Abstract][Full Text] [Related]
5. Hypotensive and natriuretic effects of nifedipine in essential hypertension. Role of renal kallikrein-kinin-prostaglandin and renin-angiotensin-aldosterone systems. Tsunoda K; Abe K; Omata K; Kudo K; Sato M; Kohzuki M; Tanno M; Seino M; Yasujima M; Yoshinaga K J Clin Hypertens; 1986 Sep; 2(3):263-70. PubMed ID: 3640807 [TBL] [Abstract][Full Text] [Related]
6. [Correlations between circulation levels of natriuretic atrial peptide and urinary excretion of kallikrein in young normotensive and hypertensive subjects]. Ferri C; Cammarella I; Giarrizzo C; Bellini C; Astorre P; Di Zenzo P; Santucci A; Musca A; Balsano F Ann Ital Med Int; 1991; 6(2):217-23. PubMed ID: 1836137 [TBL] [Abstract][Full Text] [Related]
7. Modulation of natriuresis and renal dopamine excretion by sympathetic activity and the renin-angiotensin-aldosterone system. Barendregt JN; van Nispen tot Pannerden LA; Chang PC J Hum Hypertens; 1994 Oct; 8(10):747-54. PubMed ID: 7837211 [TBL] [Abstract][Full Text] [Related]
8. Haemodynamic (systemic and renal) and humoral interactions between nicardipine and domperidone in hypertensives. Lucarini AR; Salvetti A J Hypertens Suppl; 1987 Dec; 5(5):S571-4. PubMed ID: 3327930 [TBL] [Abstract][Full Text] [Related]
9. Renin-angiotensin and kallikrein-kinin systems in sodium homeostasis and hypertension in rats. Johnston CI; Matthews PG; Dax E Clin Sci Mol Med Suppl; 1976 Dec; 3():283s-286s. PubMed ID: 1071628 [TBL] [Abstract][Full Text] [Related]
10. Urinary kallikrein and plasma renin activity as determinants of renal blood flow. The influence of race and dietary sodium intake. Levy SB; Lilley JJ; Frigon RP; Stone RA J Clin Invest; 1977 Jul; 60(1):129-38. PubMed ID: 874078 [TBL] [Abstract][Full Text] [Related]
11. Relationships among urinary kallikrein, mineralocorticoids and human hypertensive disease. Margolius HS; Horwitz D; Pisano JJ; Keiser HR Fed Proc; 1976 Feb; 35(2):203-6. PubMed ID: 1248655 [TBL] [Abstract][Full Text] [Related]
12. Studies on the natriuretic effect of nifedipine in hypertensive patients: increase in levels of plasma atrial natriuretic factor without participation of the renal kallikrein-kinin system. Rappelli A; Dessì-Fulgheri P; Madeddu P; Glorioso N J Hypertens Suppl; 1987 Dec; 5(4):S61-5. PubMed ID: 2450187 [TBL] [Abstract][Full Text] [Related]
14. [Hypertensive subpopulations as defined by their natriuretic response to ambulation]. Martín-Sanz V; Pàmies E; Muñiz-Grijalvo O; Stieffel P; Miranda ML; Villar J; Jiménez L; García de Pesquera F; Carneado J Med Clin (Barc); 1997 Jan; 108(2):50-3. PubMed ID: 9064417 [TBL] [Abstract][Full Text] [Related]
15. The renal kallikrein-kinin system and the regulation of salt and water excretion. Mills IH; Macfarlane NA; Ward PE; Obika LF Fed Proc; 1976 Feb; 35(2):181-8. PubMed ID: 765162 [TBL] [Abstract][Full Text] [Related]
16. Effects of an orally active converting enzyme inhibitor (YS-980) on renal function in dogs. Abe Y; Miura K; Imanishi M; Yukimura T; Komori T; Okahara T; Yamamoto K J Pharmacol Exp Ther; 1980 Jul; 214(1):166-70. PubMed ID: 6156237 [TBL] [Abstract][Full Text] [Related]
17. Segmental nephron function in rats treated with aprotinin, an inhibitor of kallikrein. Kauker ML; Nasjletti A J Pharmacol Exp Ther; 1986 Jul; 238(1):155-8. PubMed ID: 3636397 [TBL] [Abstract][Full Text] [Related]
18. Regulation of glomerular filtration in essential hypertension: role of abnormal Na+ transport and atrial natriuretic peptide. Semplicini A; Ceolotto G; Sartori M; Maresca A; Baritono E; De Toni R; Paparella I; Calò L J Nephrol; 2002; 15(5):489-96. PubMed ID: 12455714 [TBL] [Abstract][Full Text] [Related]
19. Effect of sodium depletion on active renin, inactive renin and prekallikrein in plasma and urinary kallikrein excretion in glomerulonephritic patients. Tsai TJ; Chen WY; Yen TS J Formos Med Assoc; 1990 May; 89(5):341-5. PubMed ID: 1977841 [TBL] [Abstract][Full Text] [Related]